Role of IL-33 in inflammation and disease

Journal of Inflammation

Volumn 8, Issue , 2011, Pages

  Miller, Ashley M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 5; METHOTREXATE; NUCLEAR FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACUTE HEART INFARCTION; ANAPHYLAXIS; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; CARDIOVASCULAR DISEASE; CELL DEATH; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENTERITIS; EPITHELIUM CELL; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNE SYSTEM; INFLAMMATORY DISEASE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NERVOUS SYSTEM INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOARTHRITIS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH2 CELL; THORAX PAIN; TISSUE INJURY; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 80052026760     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-8-22     Document Type: Review

References (123)

1. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. Onda H, Kasuya H, Takakura K, Hori T, Imaizumi T, Takeuchi T, Inoue I, Takeda J, J Cereb Blood Flow Metab 1999 19 1279 1288 10566975 (Pubitemid 30176457)
2. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Baekkevold ES, Roussigne M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, Brandtzaeg P, Erard M, Haraldsen G, Girard JP, Am J Pathol 2003 163 69 79 10.1016/S0002-9440(10)63631-0 12819012 (Pubitemid 36759592)
3. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al. Immunity 2005 23 479 490 10.1016/j.immuni.2005. 09.015 16286016 (Pubitemid 41587888)
4. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA, J Immunol 2007 179 2551 2555 17675517
5. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU, Proc Natl Acad Sci USA 2007 104 18660 18665 10.1073/pnas. 0705939104 18003919 (Pubitemid 350210753)
6. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, Gabay C, Smith DE, Cytokine 2008 42 358 364 10.1016/j.cyto.2008.03.008 18450470
7. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. Hayakawa H, Hayakawa M, Kume A, Tominaga S, J Biol Chem 2007 282 26369 26380 10.1074/jbc.M704916200 17623648 (Pubitemid 47443815)
8. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, Tominaga S, Biochem Biophys Res Commun 2001 285 1377 1383 10.1006/bbrc.2001.5306 11478810 (Pubitemid 32912936)
9. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. Bulek K, Swaidani S, Qin J, Lu Y, Gulen MF, Herjan T, Min B, Kastelein RA, Aronica M, Kosz-Vnenchak M, Li X, J Immunol 2009 182 2601 2609 10.4049/jimmunol.0802729 19234154
10. Interleukin-33-cytokine of dual function or novel alarmin? Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM, Trends Immunol 2009 30 227 233 10.1016/j.it.2009.03.003 19359217
11. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP, Proc Natl Acad Sci USA 2007 104 282 287 10.1073/pnas.0606854104 17185418 (Pubitemid 46068023)
12. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. Roussel L, Erard M, Cayrol C, Girard JP, EMBO Rep 2008 9 1006 1012 10.1038/embor.2008.145 18688256
13. Interleukin-33 is biologically active independently of caspase-1 cleavage. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G, J Biol Chem 2009 284 19420 19426 10.1074/jbc.M901744200 19465481
14. Identification of constitutively active IL-33 splice variant. Hong J, Bae S, Jhun H, Lee S, Choi J, Kang T, Kwak A, Hong K, Kim E, Jo S, Kim S, J Biol Chem 2011
15. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Cayrol C, Girard JP, Proc Natl Acad Sci USA 2009 106 9021 9026 10.1073/pnas.0812690106 19439663
16. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, Brumatti G, Taylor RC, Kersse K, Vandenabeele P, et al. Immunity 2009 31 84 98 10.1016/j.immuni.2009.05.007 19559631
17. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, Okumura K, Saito H, Nakae S, J Immunol 2009 183 7890 7897 10.4049/jimmunol.0802449 19933859
18. IL-33 raises alarm. Lamkanfi M, Dixit VM, Immunity 2009 31 5 7 10.1016/j.immuni.2009.06.011 19604486
19. IL-33 is a crucial amplifier of innate rather than acquired immunity. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, Nambu A, Abe T, Kiyonari H, Matsumoto K, et al. Proc Natl Acad Sci USA 2010 107 18581 18586 10.1073/pnas.1003059107 20937871
20. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. Xu D, Chan WL, Leung BP, Huang F, Wheeler R, Piedrafita D, Robinson JH, Liew FY, J Exp Med 1998 187 787 794 10.1084/jem.187.5.787 9480988 (Pubitemid 28115194)
21. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A, Kamradt T, Proc Natl Acad Sci USA 1998 95 6930 6935 10.1073/pnas.95.12.6930 9618516 (Pubitemid 28278084)
22. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Lecart S, Lecointe N, Subramaniam A, Alkan S, Ni D, Chen R, Boulay V, Pene J, Kuroiwa K, Tominaga S, Yssel H, Eur J Immunol 2002 32 2979 2987 10.1002/1521-4141(2002010)32:10<2979::AID-IMMU2979>3.0.CO;2-5 12355452 (Pubitemid 35238191)
23. IL-33-activated dendritic cells induce an atypical TH2-type response. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H, J Allergy Clin Immunol 2009 123 1047 1054 10.1016/j.jaci.2009.02.026 19361843
24. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, Komai-Koma M, Pitman N, Li Y, Niedbala W, et al. J Immunol 2008 181 4780 4790 18802081
25. IL-33 is a chemoattractant for human Th2 cells. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY, Eur J Immunol 2007 37 2779 2786 10.1002/eji.200737547 17853410 (Pubitemid 47578297)
26. IL-33 reduces the development of atherosclerosis. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY, J Exp Med 2008 205 339 346 10.1084/jem.20071868 18268038 (Pubitemid 351281600)
27. IL-33 activates B1 cells and exacerbates contact sensitivity. Komai-Koma M, Gilchrist DS, McKenzie AN, Goodyear CS, Xu D, Liew FY, J Immunol 2011 186 2584 2591 10.4049/jimmunol.1002103 21239718
28. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H, J Allergy Clin Immunol 2008 121 1484 1490 10.1016/j.jaci.2008.04.005 18539196 (Pubitemid 351787349)
29. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G, J Immunol 2007 179 2051 2054 17675461
30. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, Saito H, Galli SJ, Nakae S, Lab Invest 2007 87 971 978 10.1038/labinvest.3700663 17700564 (Pubitemid 47429189)
31. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE, Int Immunol 2008 20 1019 1030 10.1093/intimm/dxn060 18550585
32. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. Schneider E, Petit-Bertron AF, Bricard R, Levasseur M, Ramadan A, Girard JP, Herbelin A, Dy M, J Immunol 2009 183 3591 3597 10.4049/jimmunol. 0900328 19684081
33. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA Jr, Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ, Liew FY, Nat Med 2010 16 708 712 10.1038/nm.2156 20473304
34. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, Pitman N, Mirchandani A, Rana B, van Rooijen N, et al. J Immunol 2009 183 6469 6477 10.4049/jimmunol.0901575 19841166
35. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM, McKenzie AN, Kanellopoulos J, J Immunol 2009 183 1446 1455 10.4049/jimmunol.0803067 19553541
36. Organ-specific distribution of CD4+ T1/ST2+ Th2 cells in Leishmania major infection. Kropf P, Bickle Q, Herath S, Klemenz R, Muller I, Eur J Immunol 2002 32 2450 2459 10.1002/1521-4141(200209)32:9<2450::AID-IMMU2450>3.0.CO;2-O 12207329
37. Signaling through the T1/ST2 molecule is not necessary for Th2 differentiation but is important for the regulation of type 1 responses in nonhealing Leishmania major infection. Kropf P, Herath S, Klemenz R, Muller I, Infect Immun 2003 71 1961 1971 10.1128/IAI.71.4.1961-1971.2003 12654814 (Pubitemid 36368729)
38. IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Jones LA, Roberts F, Nickdel MB, Brombacher F, McKenzie AN, Henriquez FL, Alexander J, Roberts CW, Eur J Immunol 2010 40 426 436 10.1002/eji.200939705 19950183
39. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK, J Immunol 2008 180 2443 2449 18250453
40. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, Locksley RM, Proc Natl Acad Sci USA 2010 107 11489 11494 10.1073/pnas.1003988107 20534524
41. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, et al. Nature 2010 464 1367 1370 10.1038/nature08900 20200518
42. IL-33 family members and asthma-bridging innate and adaptive immune responses. Lloyd CM, Curr Opin Immunol 2010 22 800 806 10.1016/j.coi.2010.10.006 21071194
43. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, Lemiere C, Martin JG, Hamid Q, J Immunol 2009 183 5094 5103 10.4049/jimmunol.0802387 19801525
44. Increased IL-33 expression by epithelial cells in bronchial asthma. Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, Martin JG, Hamid Q, J Allergy Clin Immunol 2010
45. IL-33 Mediates Inflammatory Responses in Human Lung Tissue Cells. Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, Matsumoto K, Saito H, Matsuda A, J Immunol 2010
46. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, Hoshino T, Fujimoto J, Nakanishi K, Int Immunol 2008 20 791 800 10.1093/intimm/dxn037 18448455 (Pubitemid 351791523)
47. IL-33 exacerbates eosinophil-mediated airway inflammation. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY, J Immunol 2010 185 3472 3480 10.4049/jimmunol.1000730 20693421
48. Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. Zhiguang X, Wei C, Steven R, Wei D, Wei Z, Rong M, Zhanguo L, Lianfeng Z, Immunol Lett 2010 131 159 165 10.1016/j.imlet.2010.04.005 20412815
49. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T, Biochem Biophys Res Commun 2009 386 181 185 10.1016/j.bbrc.2009.06.008 19508862
50. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, Ottoson P, Persson P, Delaney T, Lehar S, et al. J Exp Med 1999 190 895 902 10.1084/jem.190.7.895 10510079 (Pubitemid 29480818)
51. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. Hoshino K, Kashiwamura S, Kuribayashi K, Kodama T, Tsujimura T, Nakanishi K, Matsuyama T, Takeda K, Akira S, J Exp Med 1999 190 1541 1548 10.1084/jem.190.10.1541 10562328
52. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Mangan NE, Dasvarma A, McKenzie AN, Fallon PG, Eur J Immunol 2007 37 1302 1312 10.1002/eji.200636520 17407196 (Pubitemid 46925314)
53. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, Bourne P, McClanahan TK, Pflanz S, de Waal Malefyt R, Int Immunol 2011
54. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, Palmer G, Joint Bone Spine 2011
55. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY, Proc Natl Acad Sci USA 2008 105 10913 10918 10.1073/pnas.0801898105 18667700
56. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C, Arthritis Rheum 2009 60 738 749 10.1002/art.24305 19248109
57. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG, J Rheumatol 2010 37 2006 2013 10.3899/jrheum.100184 20682660
58. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, Nagashima T, Hayakawa M, Iwamoto M, Yoshio T, et al. J Rheumatol 2010 37 18 25 10.3899/jrheum.090492 19918048
59. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Verri WA Jr, Souto FO, Vieira SM, Almeida SC, Fukada SY, Xu D, Alves-Filho JC, Cunha TM, Guerrero AT, Mattos-Guimaraes RB, et al. Ann Rheum Dis 2010 69 1697 1703 10.1136/ard.2009.122655 20472598
60. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Yang Z, Liang Y, Xi W, Li C, Zhong R, Clin Exp Med 2010
61. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, Lam KF, Xu D, Rheumatology (Oxford) 2010 49 520 527 10.1093/rheumatology/kep402
62. IL-33 Exacerbates Autoantibody-Induced Arthritis. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, Mu R, Tay HK, McKenzie AN, McInnes IB, et al. J Immunol 2010 184 2620 2626 10.4049/jimmunol.0902685 20139274
63. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Mun SH, Ko NY, Kim HS, Kim JW, Kim do K, Kim AR, Lee SH, Kim YG, Lee CK, Lee SH, et al. Cell Mol Life Sci 2010 67 3883 3892 10.1007/s00018-010-0410-y 20532808
64. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. Schulze J, Bickert T, Beil FT, Zaiss MM, Albers J, Wintges K, Streichert T, Klaetschke K, Keller J, Hissnauer TN, et al. J Bone Miner Res 2010
65. Interleukin-33, a Target of Parathyroid Hormone and Oncostatin M, Increases Osteoblastic Matrix Mineral Deposition and Inhibits Osteoclast Formation in Vitro. Saleh H, Eeles D, Hodge JM, Nicholson GC, Gu R, Pompolo S, Gillespie MT, Quinn JM, Endocrinology 2011
66. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Saidi S, Bouri F, Lencel P, Duplomb L, Baud'huin M, Delplace S, Leterme D, Miellot F, Heymann D, Hardouin P, et al. Cytokine 2011 53 347 354 10.1016/j.cyto.2010.11.021 21190867
67. The cytokine interleukin-33 mediates anaphylactic shock. Pushparaj PN, Tay HK, H'Ng SC, Pitman N, Xu D, McKenzie A, Liew FY, Melendez AJ, Proc Natl Acad Sci USA 2009 106 9773 9778 10.1073/pnas.0901206106 19506243
68. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, et al. Proc Natl Acad Sci USA 2010
69. IL-33 induces skin inflammation with mast cell and neutrophil activation. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, Graham GJ, Miller AM, McInnes IB, Eur J Immunol 2011
70. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S, Clin Rheumatol 2011
71. IL-33 induces IL-13-dependent cutaneous fibrosis. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK, Bourne PA, Pierce RH, Kastelein R, Pflanz S, J Immunol 2010 184 1526 1535 10.4049/jimmunol.0903306 20042577
72. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Sponheim J, Pollheimer J, Olsen T, Balogh J, Hammarstrom C, Loos T, Kasprzycka M, Sorensen DR, Nilsen HR, Kuchler AM, et al. Am J Pathol 2010 177 2804 2815 10.2353/ajpath.2010.100378 21037074
73. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Verri WA Jr, Guerrero AT, Fukada SY, Valerio DA, Cunha TM, Xu D, Ferreira SH, Liew FY, Cunha FQ, Proc Natl Acad Sci USA 2008 105 2723 2728 10.1073/pnas.0712116105 18250323 (Pubitemid 351520580)
74. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT, Proc Natl Acad Sci USA 2010 107 8017 8022 10.1073/pnas.0912678107 20385815
75. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C, Lopez F, Gonzalez MJ, Quera R, Hermoso MA, Inflamm Bowel Dis 2009
76. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama Y, Andoh A, J Gastroenterol 2010 45 999 1007 10.1007/s00535-010-0245-1 20405148
77. IL-33 is upregulated in colonocytes of ulcerative colitis. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH, Immunol Lett 2010 128 80 85 10.1016/j.imlet.2009.11.001 19913053
78. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Ajdukovic J, Tonkic A, Salamunic I, Hozo I, Simunic M, Bonacin D, Hepatogastroenterology 2010 57 1442 1444 21443100
79. TGF-beta limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. Rani R, Smulian AG, Greaves DR, Hogan SP, Herbert DR, Eur J Immunol 2011
80. Induction of IL-33 expression and activity in central nervous system glia. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT, J Leukoc Biol 2008 84 631 643 10.1189/jlb.1207830 18552204
81. Production and functions of IL-33 in the central nervous system. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, Sonobe Y, Takeuchi H, Mizuno T, Suzumura A, Brain Res 2011 1385 8 17 21349253
82. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, Maurage CA, Huot L, Bensemain F, Laumet G, et al. Mol Psychiatry 2009 14 1004 1016 10.1038/mp.2009.10 19204726
83. Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease. Yu JT, Song JH, Wang ND, Wu ZC, Zhang Q, Zhang N, Zhang W, Xuan SY, Tan L, Neurobiol Aging 2010
84. Studies on natural ST2 gene products in the human leukemic cell line UT-7 using monoclonal antihuman ST2 antibodies. Yoshida K, Arai T, Yokota T, Komatsu N, Miura Y, Yanagisawa K, Tetsuka T, Tominaga S, Hybridoma 1995 14 419 427 10.1089/hyb.1995.14.419 8575790
85. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Tsuchiya T, Ohshima K, Karube K, Yamaguchi T, Suefuji H, Hamasaki M, Kawasaki C, Suzumiya J, Tomonaga M, Kikuchi M, Blood 2004 103 236 241 10.1182/blood-2002-05-1352 12958063 (Pubitemid 38029944)
86. ST2 Deletion Enhances Innate and Acquired Immunity to Murine Mammary Carcinoma. Jovanovic I, Radosavljevic G, Mitrovic M, Lisnic Juranic V, McKenzie A, Arsenijevic N, Jonjic S, Lukic M, Eur J Immunol 2011
87. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, Kim J, Kim YM, Kwon YG, Blood 2009 114 3117 3126 10.1182/blood-2009-02-203372 19661270
88. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Kuchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR, De Angelis PM, Scott H, Haraldsen G, Am J Pathol 2008 173 1229 1242 10.2353/ajpath.2008.080014 18787100
89. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B, Croes R, Verstreken S, Goethals M, de Raedt H, et al. J Am Coll Cardiol 2008 52 2166 2174 10.1016/j.jacc.2008.09.027 19095135
90. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? Moussion C, Ortega N, Girard JP, PLoS One 2008 3 3331 10.1371/journal.pone.0003331 18836528
91. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Wood IS, Wang B, Trayhurn P, Biochem Biophys Res Commun 2009 384 105 109 10.1016/j.bbrc.2009.04.081 19393621
92. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT, J Clin Invest 2007 117 1538 1549 10.1172/JCI30634 17492053 (Pubitemid 46871338)
93. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT, Circulation 2002 106 2961 2966 10.1161/01.CIR.0000038705.69871.D9 12460879 (Pubitemid 35424749)
94. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA, Clin Chem 2009 55 1108 1117 10.1373/clinchem.2009.123935 19372185
95. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT, Circ Heart Fail 2009 2 684 691 10.1161/CIRCHEARTFAILURE.109.873240 19919994
96. Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1. Yndestad A, Marshall AK, Hodgkinson JD, Thamel L, Sugden PH, Clerk A, Int J Biochem Cell Biol 2010 42 263 272 10.1016/j.biocel. 2009.10.021 19861169
97. The immune system in atherosclerosis. Hansson GK, Hermansson A, Nat Immunol 2011 12 204 212 21321594
98. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Davenport P, Tipping PG, Am J Pathol 2003 163 1117 1125 10.1016/S0002-9440(10)63471-2 12937153 (Pubitemid 37040147)
99. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C, J Clin Invest 1997 99 2752 2761 10.1172/JCI119465 9169506 (Pubitemid 27259823)
100. IL-33 reduces macrophage foam cell formation. McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, Liew FY, Ramji DP, J Immunol 2010 185 1222 1229 10.4049/jimmunol.1000520 20543107
101. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY, Circ Res 2010 107 650 658 10.1161/CIRCRESAHA.110.218867 20634488
102. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J, Ohtani M, Fujii H, Koyasu S, Nature 2010 463 540 544 10.1038/nature08636 20023630
103. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT, Circulation 2004 109 2186 2190 10.1161/01.CIR.0000127958.21003.5A 15117853 (Pubitemid 38625395)
104. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT, Circulation 2008 117 1936 1944 10.1161/CIRCULATIONAHA.107.728022 18378613 (Pubitemid 351543469)
105. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ, J Am Coll Cardiol 2010 55 243 250 10.1016/j.jacc.2009.08.047 20117403
106. ST2 in emergency department chest pain patients with potential acute coronary syndromes. Brown AM, Wu AH, Clopton P, Robey JL, Hollander JE, Ann Emerg Med 2007 50 153 158 158 e151. 10.1016/j.annemergmed.2007.02.015 17466411 (Pubitemid 47069601)
107. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT, Circulation 2003 107 721 726 10.1161/01.CIR.0000047274.66749.FE 12578875 (Pubitemid 36222600)
108. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M, Clin Chem 2008 54 752 756 10.1373/clinchem.2007.096560 18375488 (Pubitemid 351573718)
109. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. Rehman SU, Mueller T, Januzzi JL Jr, J Am Coll Cardiol 2008 52 1458 1465 10.1016/j.jacc.2008.07.042 19017513
110. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel AS, Fitzgerald RL, J Card Fail 2008 14 732 738 10.1016/j.cardfail.2008. 06.415 18995177
111. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, Cinca J, de Luna AB, Bayes-Genis A, J Am Coll Cardiol 2009 54 2174 2179 10.1016/j.jacc.2009.07.041 19942089
112. Biomarkers of heart failure in pleural fluid. Porcel JM, Martinez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A, Chest 2009 136 671 677 10.1378/chest.09-0270 19363209
113. Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdes Chavarri M, Ordonez-Llanos J, Rev Esp Cardiol 2010 63 1171 1178 20875357
114. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL, Am J Cardiol 2011 107 259 267 10.1016/j.amjcard.2010.09.011 21211603
115. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, et al. Circ Heart Fail 2011 4 180 187 10.1161/CIRCHEARTFAILURE.110.958223 21178018
116. Soluble ST2 protein in cardiac surgery: a possible negative feedback loop to prevent uncontrolled inflammatory reactions. Szerafin T, Brunner M, Horvath A, Szentgyorgyi L, Moser B, Boltz-Nitulescu G, Peterffy A, Hoetzenecker K, Steinlechner B, Wolner E, Ankersmit HJ, Clin Lab 2005 51 657 663 16329625 (Pubitemid 41763084)
117. Secretion of soluble ST2-possible explanation for systemic immunosuppression after heart surgery. Szerafin T, Niederpold T, Mangold A, Hoetzenecker K, Hacker S, Roth G, Lichtenauer M, Dworschak M, Wolner E, Ankersmit HJ, Thorac Cardiovasc Surg 2009 57 25 29 10.1055/s-2008-1039044 19169993
118. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Daniels LB, Clopton P, Iqbal N, Tran K, Maisel AS, Am Heart J 2010 160 721 728 10.1016/j.ahj.2010.06.033 20934567
119. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, et al. J Am Coll Cardiol 2007 50 607 613 10.1016/j.jacc.2007.05. 014 17692745 (Pubitemid 47199007)
120. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T, Clin Biochem 2010 43 714 719 10.1016/j.clinbiochem.2010.02.002 20153308
121. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O'Donoghue M, Januzzi JL, Am J Clin Pathol 2008 130 578 584 10.1309/WMG2BFRC97MKKQKP 18794051
122. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL Jr, Clin Chim Acta 2008 392 41 45 10.1016/j.cca.2008.03.002 18387360
123. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL, Circ Heart Fail 2009 2 311 319 10.1161/CIRCHEARTFAILURE.108.833707 19808354